MARKET

IBRX

IBRX

Immunitybio Inc
NASDAQ
8.64
+0.01
+0.12%
After Hours: 8.63 -0.01 -0.12% 17:51 09/24 EDT
OPEN
8.50
PREV CLOSE
8.63
HIGH
8.68
LOW
8.31
VOLUME
8.95M
TURNOVER
--
52 WEEK HIGH
12.43
52 WEEK LOW
1.950
MARKET CAP
9.16B
P/E (TTM)
-8.9155
1D
5D
1M
3M
1Y
5Y
1D
ImmunityBio’s New Bladder Cancer Combo Trial: What Investors Should Know
TipRanks · 10h ago
What 235,000 Stock Periods Suggest About Revenue Growth and Returns: Inside the Golden Eagle Dynamic Hypergrowth ETF (HYP)
TipRanks · 16h ago
ImmunityBio (IBRX) Faces Investor Scrutiny as Defendants Move to Dismiss Securities Lawsuit Over Podcast Statements
TipRanks · 17h ago
Could Tokenized Trading Change The Case For ImmunityBio Stock
Simply Wall St · 1d ago
Weekly Report: what happened at IBRX last week (0914-0918)?
Weekly Report · 3d ago
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Seeking Alpha · 4d ago
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
NASDAQ · 6d ago
ImmunityBio (IBRX) Draws Fresh Attention, Is The Stock Still Undervalued?
Simply Wall St · 6d ago
More
About IBRX
ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. The Cancer BioShield platform is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via its IL-15 receptor agonist, ANKTIVA. The Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy.

Webull offers Immunitybio Inc stock information, including NASDAQ: IBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBRX stock methods without spending real money on the virtual paper trading platform.